# Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias

> **NCT00749112** · PHASE2,PHASE3 · COMPLETED · sponsor: **Hospital Universitario Dr. Jose E. Gonzalez** · enrollment: 19 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura
- Anemia, Hemolytic, Autoimmune

## Interventions

- **DRUG:** Alemtuzumab, Rituximab

## Key facts

- **NCT ID:** NCT00749112
- **Lead sponsor:** Hospital Universitario Dr. Jose E. Gonzalez
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2010-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00749112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00749112, "Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00749112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*